BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. The company's core business model revolves around advancing its pipeline of immunotherapy candidates through clinical trials, with the ultimate goal of obtaining regulatory approvals and commercializing these treatments. Revenue generation is currently absent, as the company is in the development stage, relying on equity and debt financings to fund its operations. The primary customer segments, once products are approved, would be cancer patients, particularly those with metastatic breast cancer and prostate cancer, who have limited alternative treatment options.

The company's lead product candidate is Bria-IMT™, a whole-cell immunotherapy for metastatic breast cancer. Bria-IMT™ is currently undergoing a pivotal Phase 3 clinical study in combination with an immune checkpoint inhibitor (Retifanlimab) for advanced metastatic breast cancer patients who have failed prior lines of therapy ¹. This candidate has received Fast Track Designation from the U.S. FDA, aiming to accelerate the review process for unmet medical needs ¹. In its Phase 2 study, Bria-IMT™ in combination with a checkpoint inhibitor demonstrated a median overall survival of 13.4 months for all patients, and 16.5 months for patients treated since 2022 with the Phase 3 formulation ¹. This compares favorably to reported median overall survival rates of 6.7-9.8 months for similar patients in the literature ¹. The intracranial overall response rate (iORR) for patients with intracranial metastatic disease treated with Bria-IMT™ was 71%, significantly higher than the typical iORR of less than 20% in comparable patients ¹.

Another significant product in the pipeline is Bria-OTS™, a personalized off-the-shelf immunotherapy, also known as Bria-BRES™, which is in an ongoing Phase 1/2 study for metastatic breast cancer ¹. Bria-OTS™ is engineered to express 15 unique HLA types through four independent cell lines, aiming to provide matched treatment to over 99% of patients ¹. A notable clinical response was observed in the first patient treated with Bria-OTS™ monotherapy, showing complete resolution of a lung metastasis, which was sustained at the six-month timepoint ¹. The company is also developing enhanced versions, Bria-OTS+™, for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™), as well as breast cancer (Bria-BRES+™) ¹.

BriaCell also made strides in advancing its next-generation candidates Bria-PROS+™ and Bria-BRES+™. A successful Pre-IND meeting with the FDA for Bria-PROS+™ resulted in the waiver of requirements for animal toxicology and pharmacokinetic studies prior to opening the IND, simplifying the development pathway ¹. Preclinical data for both Bria-PROS+™ and Bria-BRES+™ demonstrated in vitro anti-cancer activity in breast and prostate cancer models ¹. Furthermore, BriaPro Therapeutics Corp., a majority-owned subsidiary of BriaCell, initiated a new program in antibody therapeutics, developing high-affinity antibodies against B7-H3, an immune checkpoint molecule ¹. These antibodies are intended to be incorporated into the proprietary Bria-TILsRx™ platform, designed to activate tumor-infiltrating lymphocytes within the tumor microenvironment ¹.

For the fiscal year ended July 31, 2025, BriaCell reported a net loss of $26,311,867 ¹⁰, compared to a net loss of $4,791,466 ¹⁰ in the prior fiscal year. The accumulated deficit as of July 31, 2025, stood at $111,755,564 ¹⁰, an increase from $85,443,697 ¹⁰ as of July 31, 2024. Total research and development expenses for the year ended July 31, 2025, were $21,270,678 ⁷, a decrease from $27,177,807 ⁷ in the previous year. General and administrative expenses were $5,934,125 ⁸ in 2025, compared to $6,152,269 ⁸ in 2024. The company's cash and cash equivalents increased to $10,493,808 ⁴ as of July 31, 2025, from $862,089 ⁴ as of July 31, 2024. Total current assets were $19,926,576 ⁴ and total current liabilities were $3,977,988 ⁴, resulting in a positive working capital of $15,948,588 ⁹ as of July 31, 2025, a significant improvement from a negative working capital of $3,807,303 ⁹ in the prior year.

The decrease in total research, development, and clinical trial costs from $27,177,807 ⁷ in 2024 to $21,270,678 ⁷ in 2025 was primarily due to lower clinical trial sites and investigational drug costs, which decreased from $20,885,903 ⁷ to $14,765,112 ⁷. This reduction reflects the conclusion of the Bria-IMT™ Phase 1/2a trial and a strategic focus on optimizing expenditures for the pivotal Phase 3 trial ⁷. Wages and salaries within R&D increased from $4,567,307 ⁷ to $5,356,806 ⁷, indicating additional hiring. Share-based compensation expenses decreased significantly from $734,986 ⁷ in 2024 to $120,050 ⁷ in 2025. The increase in net loss was primarily driven by a significantly smaller gain on the fair value of the warrant liability, which was $758,364 ¹⁰ in 2025 compared to $28,242,472 ¹⁰ in 2024.

During the reporting period, BriaCell announced that its pivotal Phase 3 clinical study for Bria-IMT™ has consented over 100 patients and enrolled over 75 patients, with top-line data anticipated as early as H1-2026 ¹. The Data Safety Monitoring Board (DSMB) completed its first, second, and third reviews of safety events, recommending continuation of the Phase 3 study with no safety concerns ¹. The company also initiated the Bria-OTS™ Phase 1/2a trial in August 2024, with the first patient treated demonstrating complete resolution of a lung metastasis ¹. BriaCell's subsidiary, BriaPro Therapeutics Corp., filed a patent application for its immuno-oncology platform with novel multitargeting agents, the Bria-TILsRx™ platform ¹. The company also completed several financings, raising approximately $50.9 million in gross proceeds during the fiscal year ended July 31, 2025 ¹.

BriaCell anticipates reporting top-line data for its pivotal Phase 3 clinical study of Bria-IMT™ as early as H1-2026 ¹. The FDA has agreed that improvement in overall survival in the Bria-IMT™ combination arm compared to the physician's choice of treatment arm will be the primary endpoint of the study ¹. The study is expected to enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in the treatment of physician's choice arm, with an additional 50 patients in the Bria-IMT™ regimen alone arm for further information ¹. An interim evaluation for efficacy is planned, which could lead to early completion of the study if the hazard ratio (HR) is less than or equal to 0.6, allowing for a Biologics Licensing Application (BLA) submission ¹. If the HR is greater than 0.6, the study will continue to completion with an HR target of 0.7 ¹.

A major growth area for BriaCell is the advancement of its Bria-IMT™ targeted immunotherapy, which is currently in a pivotal Phase 3 study for metastatic breast cancer ¹. This program has Fast Track Designation from the FDA, which is intended to accelerate the review process for novel treatments addressing unmet medical needs ¹. Positive completion of this pivotal study, following FDA review, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer ¹. The company has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.4 months in BriaCell's metastatic breast cancer patients versus 6.7-9.8 months for similar patients reported in the literature in its Phase 2 study of Bria-IMT™ combination study with retifanlimab ¹.

Another key growth vector is the development of Bria-OTS™, the company's personalized off-the-shelf immunotherapy, also known as Bria-BRES™, which is in an ongoing Phase 1/2 study in metastatic breast cancer ¹. Bria-OTS™ is designed to express 15 unique HLA types through four independent cell lines, aiming to provide matched treatment to over 99% of patients ¹. The company has observed a complete resolution of a lung metastasis in the first patient treated with Bria-OTS™ as a single agent, which was sustained at the six-month timepoint ¹. BriaCell is also developing enhanced versions, Bria-OTS+™, for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™), with IND filings for these immunotherapy cell lines anticipated starting in late 2025 or early 2026 ¹. The company received positive feedback from its Pre-IND meeting with the FDA for Bria-PROS+™ for prostate cancer, with the FDA waiving requirements for animal toxicology and pharmacokinetic studies ¹.

Operationally, BriaCell expects operating expenses and staffing levels to continue to increase as it advances its clinical programs, scales its operations, and prepares for potential commercialization of its product candidates ¹. The company is actively recruiting additional clinical sites in collaboration with Prevail InfoWorks, Inc. to speed up the patient recruitment process for its pivotal Phase 3 study ¹. BriaCell relies on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidates for its clinical trials, with Bria-IMT™ currently manufactured under cGMP by UC Davis and FujiFilm Diosynth Biotechnology ¹. The company also entered into an agreement with Waisman Biomanufacturing to manufacture Bria-Pros™ for anticipated use in clinical studies ¹.

The company anticipates that additional capital will be required to complete its current research and development programs, including future research, additional pre-clinical and toxicology studies, and manufacturing initiatives to prepare for market approval and successful product launch ¹. During the year ended July 31, 2025, the company raised approximately $50.9 million in gross proceeds from equity financings ¹. BriaCell's investment policy and strategy are focused on preservation of capital and supporting its liquidity requirements ⁹.

BriaCell faces substantial risks, including the inherent uncertainty of clinical trials where favorable early results may not predict outcomes in later, larger studies, potentially delaying or terminating product development ¹. The company is heavily reliant on third-parties for manufacturing, pharmaceutical development, and marketing, and any failure by these contractors to meet supply requirements, perform clinical trials, or market products effectively could severely harm the business ¹. Intellectual property risks are significant, as the company may not successfully develop, maintain, or protect its proprietary products and technologies, and could be susceptible to costly intellectual property suits or challenges to its patents ¹. Regulatory risks are also material, as changes in legislation and regulations could affect revenue and profitability, and the inability to obtain U.S., Canadian, or foreign regulatory approvals for product candidates would prevent commercialization ¹. Furthermore, modifications to approved products may require new regulatory clearances or recalls ¹. Financially, there is substantial doubt about the company's ability to continue as a going concern, having incurred significant losses of $26,311,867 ¹⁰ in fiscal year 2025 and an accumulated deficit of $111,755,564 ¹⁰ as of July 31, 2025, and it will require additional capital to fund operations, which may not be available on acceptable terms and could dilute existing shareholders ¹. The company also faces an unproven market for its product candidates, and its growth may strain managerial, operational, financial, and technical resources ¹. Global economic uncertainty and financial market volatility, including geopolitical instability and conflicts, could make it more difficult to access financing and disrupt supply chains, while inflation could increase overall cost structure ¹.

Management's message emphasizes BriaCell's commitment as a clinical-stage biotechnology company to developing novel immunotherapies for cancer care, leveraging the body's immune system to combat cancer cells. They highlight the ongoing pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer, noting its Fast Track Designation by the FDA, which is intended to accelerate the review process for novel treatments addressing unmet medical needs ¹. Management anticipates reporting top-line data from this Phase 3 study as early as H1-2026 ¹. A key strategic priority is the successful completion of this pivotal study, as positive results could lead to full FDA approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer ¹. Another strategic priority is the continued development of personalized off-the-shelf immunotherapies, such as Bria-OTS™ and Bria-OTS+™, with IND filings for these immunotherapy cell lines anticipated starting in late 2025 or early 2026 ¹. Management also underscores the diversification of the pipeline through its majority-owned subsidiary, BriaPro Therapeutics Corp., which is developing high-affinity antibodies against B7-H3 and integrating them into the Bria-TILsRx™ platform ¹.